Most GLP-1 medicines are administered via subcutaneous injection, either daily or weekly depending on the specific formulation, though oral semaglutide (Rybelsus) is also available
In contrast, long-acting molecules, such as liraglutide, SMG, dulaglutide, and tirzepatide, provide continuous receptor activation, resulting in prolonged appetite suppression and insulinotropic effects
Any ideas
It is thought to be the result of the stomach's GLP-1 receptors that regulate its emptying and motility (contractions)
Vascul Pharmacol 43:404410 Demarco VG, Scumpia PO, Bosanquet JP, Skimming JW (2004) -Lipoic acid inhibits endotoxin-stimulated expression of iNOS and nitric oxide independent of the heat shock response in RAW 264.7 cells
This paper provides a review on the current evidence supporting the use of GLP-1 in experimental animal models and human trials with the ischemic and non-ischemic heart and discusses their molecular mechanisms and potential as a new therapeutic approach
